US Patent Issued to Dana-Farber Cancer Institute on Nov. 11 for "Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides" (Massachusetts, New Hampshire Inventors)

ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,466,853, issued on Nov. 11, was assigned to Dana-Farber Cancer Institute Inc. (Boston).

"Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides" was invented by Loren D. Walensky (Newton, Mass.), Gregory H. Bird (Pelham, N.H.), Rachel Guerra (Cambridge, Mass.) and Edward Harvey (Weston, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure features structurally-stabilized and/or cysteine-reactive peptide inhibitors for selective targeting of BFL-1, or dual targeting of BFL-1 and MCL-1. Also disclosed are methods of using such structurally-stabilized and cysteine-reactive peptides in the...